[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-tumor---metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-tumor---metastatic":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,40,92,121,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100379552","phase-2-a-study-comparing-gliadel-to-stereotactic-radiosurgery-in-metastatic-brain-disease-100379552",false,"NCT04222062","A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease","A Randomized Trial Evaluating GLIADEL Compared to Stereotactic Radiosurgery in Subjects With Metastatic Brain Disease","Inclusion criteria:\n\n* Age 18 years or older (in states with 18 as age of majority); Age 19 years or older in Nebraska (age of majority)\n* Recursive partitioning analysis (RPA) class I, II or III with a Karnofsky Performance Status (KPS) of \\>\u002F 60\n* Known or suspected primary solid cancer with metastatic brain tumor(s) - up to four in number and up to 4 cm in size with surgical resection planned for at least one site with Gliadel placement planned for only one site\n* Laboratory values adequate for patient to undergo surgery safely as determined by the attending neurosurgeon (transfusion permitted to reach goals)\n* Women of childbearing potential must have a negative pregnancy test within 7 days of initiating study. (No childbearing potential is defined as age 55 years or older and no menses for two years or any age with surgical removal of the uterus and\u002For both ovaries)\n* Normal coagulation studies (international normalized ratio, INR, ≤ 1.3)\n* Estimated survival time of ≥ 3 months (determined by the participant's primary oncologist)\n* Participant is willing and able to consent and abide by the protocol\n\nExclusion criteria:\n\n* Prior treatment to the area of planned resection (surgery, radiation)\n* Prior whole brain radiation therapy\n* Diagnosis of lymphoma, germ cell cancer, small cell lung cancer, anaplastic thyroid cancer\n* Leptomeningeal disease\n* Neurodegenerative disorder (e.g. dementia)\n* Tumor size \\> 4 cm\n* Karnofsky Performance Status (KPS) \\\u003C 60\n* Inability or unwillingness to co-operate with the requirements of the protocol\n* Any other clinically significant medical disease or condition, laboratory abnormality or psychiatric illness that, in the Investigator's opinion, may interfere with protocol adherence or confound efficacy or safety assessment or a subject's ability to give informed consent\n* Simultaneous participation in other therapeutic clinical trials\n* Severe pulmonary, cardiac or other systemic disease, specifically:\n\n  * New York Heart Association \\> Grade 2 congestive heart failure within 6 months prior to study entry, unless asymptomatic and well controlled with medication\n  * Uncontrolled or significant cardiovascular disease, clinically significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades des pointes), clinically significant pulmonary disease (such as ≥ Grade 2 dyspnea, according to Common Terminology Criteria for Adverse Events 5.0)\n* Participants having any other disease, either metabolic or psychological, which as per Investigator assessment may affect the participant's compliance or place the participant at higher risk of potential treatment complications\n* Participant has a bleeding diathesis, or must take anticoagulants, or antiplatelet agents including non-steroidal anti-inflammatory drugs (NSAIDs) at the time of scheduled resection that cannot be stopped for surgery\n* Inability to obtain MRI studies","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.",[26],"Brain Tumor - Metastatic","RECRUITING","2026-04-27",{"date":30,"type":31},"2026-04-28","ACTUAL",{"date":33,"type":31},"2020-11-06",{"date":35,"type":20},"2029-12",{"name":37,"class":38},"University of Nebraska","OTHER",2,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":91},"100603105","phase-2-stereotactic-radiation-for-growingchanging-brain-metastases-with-same-day-radiation-planning-and-treatment-with-margin-reduction-100603105","NCT07132190","Stereotactic Radiation for Growing\u002FChanging Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction","A Double-Blind Phase II Randomized Study of Adaptively Delivered LINAC-Based Stereotactic Radiation for Volatile Brain Metastases With Same-Day Planning and Margin Reduction","Inclusion Criteria:\n\n1. Participants must have a biopsy proven solid malignancy with at least one intact, residual or recurrent, intracranial lesion radiographically consistent with or pathologically proven to be a brain metastasis meeting one of the following criteria:\n\n   1. Growth of 1.0mm per week or more, on average, based on the two most recent brain MRIs preceding study enrollment\n   2. Abutment, to within 1.0cm, of a region of intracranial edema\n   3. Proximity (within 5.0cm) to a surgical cavity created within 30 days of enrollment\n   4. Proximity (within 5.0cm) to another source of physical displacement\n2. Age of at least 18 years\n3. Karnofsky performance status of at least 60\n4. Estimated survival of at least 3-6 months in the opinion of the enrolling clinician and\u002For study PI\n5. Ability to understand and the willingness to sign a written informed consent document by either ink on paper or a DF\u002FHCC approved eConsent medium\n\nExclusion Criteria:\n\n1. Participants who cannot tolerate a brain MRI\n2. Patients who cannot receive gadolinium\n3. Participants with end stage renal disease\n4. Participants with widespread, definitive leptomeningeal disease\n5. Pregnant women are excluded from this study because of the potential deleterious effects of gadolinium on the developing fetus. Because there is an unknown but potential risk for adverse events in nursing infants, women who are breastfeeding are not eligible for this study as well",{"count":48,"type":20},60,[23],"The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation treatment. The intent of this shorter time interval is to increase the likelihood that the brain metastases being treated remain fully within the high-dose radiation fields.\n\nParticipants will be randomized to receive brain-directed stereotactic radiation with a 1mm margin or 0mm margin, have their simulation\u002Fradiation planning imaging on the same day that brain-directed stereotactic radiation is delivered, and have repeat simulation\u002Fradiation planning scans during the course of treatment if more than 2-3 days have elapsed since the most recent scans.",[52,26,53,54],"Brain Metastases, Adult","Brain Metastases From Non-small Cell Lung Cancer (NSCLC)","Brain Metastases From Extra-cranial Solid Tumors",[56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81],"Brain Mets","Brain Metastases","Brain-directed stereotactic radiation","Brain radiation","Volatile Brain Metastases","Intracranial lesion","SRS","SRT","RANO","PTV","Planning Target Volume","Local Recurrence","Radiation Necrosis","Adaptive","VMAT","Volumetric Modulated Arc Therapy","Margin","Volatile","Rapid","Growth","Shift","neurocognitive","quality of life","survival","same day","randomized","2026-03-17",{"date":84,"type":31},"2026-03-19",{"date":86,"type":31},"2025-12-30",{"date":88,"type":20},"2029-09",{"name":90,"class":38},"Ayal A. Aizer, MD",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":99,"targetDuration":101,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":120},"100395308","registry-of-patients-with-brain-tumors-treated-with-start-gammatiles-100395308","NCT04427384","Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)","A Multicenter Observational Study of GammaTile™ Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms","Inclusion Criteria:\n\n1. Patients who undergo maximum safe resection of intracranial neoplasm(s) AND implantation of GammaTiles.\n2. Willing and able to provide informed consent and to participate in all evaluations.\n\nExclusion Criteria:\n\n1. Inability to undergo pre-operative and post-operative imaging for disease and implant assessment.\n2. Major medical or psychiatric illness, which, in the investigator's opinion would prevent completion of treatment, ability to complete assessments at the time of enrollment, and\u002For interfere with follow ups.\n3. Subjects who, in the investigator's opinion, are unable to understand the protocol or to give informed consent, have a history of poor cooperation, noncompliance with medical treatment, or difficulty in returning for follow up care. A legally authorized representative may provide consent if the potential subject lacks the capacity to provide consent themselves.",{"count":100,"type":20},600,"5 Years","OBSERVATIONAL","The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.",[105,106,107,26,108,109],"Brain Tumor, Recurrent","Brain Tumor","Brain Tumor, Primary","Brain Tumor, Adult: Glioblastoma","Brain Tumor, Adult Meningioma","2026-02-11",{"date":112,"type":31},"2026-02-13",{"date":114,"type":31},"2020-09-11",{"date":116,"type":20},"2028-12-31",{"name":118,"class":119},"GT Medical Technologies, Inc.","INDUSTRY",54,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":91},"100503159","characterization-of-circulating-and-tumor-infiltrating-immune-cells-in-malignant-brain-tumors-100503159","NCT05831631","Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors","Immunophenotype Characterization of Circulating and Tumor Infiltrating Immune Cells in Malignant Brain Tumors.","Inclusion criteria:\n\n* Adult patients (≥18 years)\n* Able to express informed consent\n* With primary or secondary malignant brain tumor\n* Requiring neurosurgical treatment (radiosurgery, stereotactic biopsy, surgery)\n\nExclusion Criteria:\n\n* Patients who do not meet inclusion criteria.",{"count":129,"type":20},200,"The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the oncological outcome.\n\nParticipants will be subjected to blood sampling before surgery and for 12 months of follow-up. Additional sampling and analysis will be performed on tumor samples.",[107,26],[133,134],"Immunophenotype","Primary and secondary brain tumor","2025-06-06",{"date":137,"type":31},"2025-06-11",{"date":139,"type":31},"2022-08-01",{"date":141,"type":20},"2029-08-01",{"name":143,"class":38},"Pietro Mortini, MD, Prof.",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":159,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":4},"100587548","research-on-the-safety-and-efficacy-of-intraoperative-radiation-therapy-in-malignant-cerebral-tumor-100587548","NCT06929819","Research on the Safety and Efficacy of Intraoperative Radiation Therapy in Malignant Cerebral Tumor","Inclusion Criteria:\n\n* 18-75 years old, non-pregnant or lactating women\n* KPS ≥60\n* MRI and CT of the brain with contrast should be considered for diagnosis of high-grade glioma or other malignant brain tumors\n* No other underlying diseases that affect survival time, follow-up or quality of life, and no other serious organic lesions\n* Not receive radiotherapy, chemotherapy and other treatment methods for intracranial lesions in the past;\n* Tumor located supratentorium, and the position should ensure that the tumor resection volume is more than 90%;\n* The required dose of standard radiotherapy exceeds normal tissue tolerance\n* No related contraindications such as intraoperative radiotherapy and craniotomy.\n\nExclusion Criteria:\n\n* Refuse to undergo craniotomy or radiation therapy;\n* The postoperative paraffin pathological results were not high-grade gliomas or other cranial malignant tumors;\n* Refuse to participate in the clinical trial after informed consent without the above exclusion criteria.","75 Years",{"count":129,"type":20},[153],"NA","According to the latest national cancer statistics released by the National Cancer Center in February 2022, intracranial tumors account for about 60%-70% of the more than 3.5 million cancer patients, and the morbidity and mortality remain high. Intracranial malignant tumors have become a problem that needs to be solved urgently because of their early recurrence, rapid progression, and short survival, and intracranial malignant tumors include high-grade gliomas, metastases, lymphomas, etc.\n\nGlioblastoma (GB) is the most common primary malignancy in the adult central nervous system, accounting for about 57% of all gliomas and 48% of all primary weighted nervous system malignancies. At present, the standard treatment for glioblastoma is mainly surgical treatment, supplemented by postoperative concurrent chemoradiotherapy and adjuvant chemotherapy, but the prognosis of patients is still poor, with a one-year survival rate of 40.6%, a five-year survival rate of only 5.6%, and an average survival time of 12-15 months.\n\nFor patients diagnosed with intracranial malignancies (including high-grade glioma, metastases, lymphoma, etc.), multimodal image-guided microsurgery combined with postoperative chemoradiotherapy recommended by the guidelines, and intraoperative radiotherapy with tumor bed radiation therapy to achieve targeted and precise tumor treatment, thereby improving the prognosis of patients (including progression-free survival and median overall survival, etc.)",[156,107,26],"Glioblastoma",[106,158],"Intraoperative Radiation Therapy","NOT_YET_RECRUITING","2025-04-15",{"date":162,"type":31},"2025-04-16",{"date":164,"type":20},"2025-06-01",{"date":166,"type":20},"2030-05-31",{"name":168,"class":38},"First Affiliated Hospital, Sun Yat-Sen University"]